Discussion
KIT2014, an experimental inhaled therapy by Kither Biotech, was safe and well tolerated in healthy volunteers, according to Phase 1 trial results, potentially supporting further development of the medication for cystic fibrosis (CF) and other lung conditions. “We are pleased to report the successful completion of this first-in-human…